Where Will Eli Lilly Be in 10 Years?

Eli Lilly has surged to the front of the fast‑growing GLP‑1 market—overtaking Novo Nordisk—on the back of Mounjaro (+109% YoY sales in Q3 2025) and Zepbound (+185%), which helped lift total sales 54%; however the stock trades at a rich P/E (~50 vs. S&P ~28.5) and those two drugs now generate more than half of company revenue, creating concentration risk. With roughly a decade until key patents expire and competitors such as Pfizer aggressively pursuing GLP‑1 candidates (via deals and acquisitions), Lilly faces meaningful downside if it loses market leadership or cannot replace these blockbusters, despite efforts to develop new molecules and extend protections. The article advises caution for new investors given the stock’s premium valuation and the binary, time‑limited nature of its core assets.

Analysis

Eli Lilly has become the market leader in GLP-1 therapies on the back of exceptionally strong recent sales: Mounjaro grew 109% year‑over‑year in Q3 2025 and Zepbound rose 185%, driving total company sales up 54%. The company now derives more than half of top‑line revenue from these two drugs, making current performance highly concentrated in the GLP‑1 franchise.

The stock trades at a rich P/E of about 50 (below its five‑year average of 54 but well above the S&P 500 at 28.5), while peers such as Pfizer trade at materially lower multiples (P/E ~15). Competitive risk is tangible: Lilly was not first to market and competitors including Pfizer are pursuing GLP‑1 candidates via acquisitions and distribution deals, creating potential binary outcomes if rivals gain approval or superior efficacy.

Key downside is a patent cliff roughly a decade out for Mounjaro and Zepbound; generics would likely compress revenues materially. Lilly is working on new molecules and patent‑extension strategies, but given valuation and revenue concentration, investors face a lot of upside priced in today and meaningful execution and timing risk ahead.

Key Decisions for Investors

• Given >50% revenue concentration and a P/E ~50, consider trimming new or oversized positions to reduce single‑drug risk
• Watch quarterly sales cadence for Mounjaro and Zepbound and upcoming competitor regulatory/trial milestones (notably Pfizer) as potential volatility triggers
• Position size with the ~10‑year patent horizon in mind — favor partial exposure or hedges (options or pairs) rather than an undiversified long‑only stance
• If seeking GLP‑1 exposure with lower valuation risk, consider reallocating a portion of weight to lower‑multiple peers mentioned in the article (e.g., Pfizer) while monitoring pipeline differentiation